Chimeric Therapeutics Initiates Phase 1/2 Clinical Trial for CHM CDH17

Chimeric Therapeutics (ASX: CHM), a leader in cell therapy, has received ethics approval to begin a multi-site Phase 1/2 clinical trial of CHM CDH17 in patients with advanced gastrointestinal (GI) cancers. This milestone allows the trial to proceed under FDA regulations. Dr. Rebecca McQualter, Chief Operating Officer, expressed enthusiasm about this advancement for cell therapies targeting solid tumors.

CHM CDH17 is a novel, third-generation CAR T cell therapy designed to target CDH17, associated with poor prognosis in GI cancers such as colorectal and gastric cancer. Preclinical studies, published in Nature Cancer in March 2022 by Dr. Xianxin Hua and his team at the University of Pennsylvania, showed that CHM CDH17 eradicated tumors in seven cancer models without harming normal tissues. This trial is a significant step towards bringing this promising therapy to patients.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com